Asia Executives On The Move: Comings And Goings At BeiGene, Harbour BioMed, TLC, GC Pharma
New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure of BeiGene's chief commercial officer and a new chief strategy officer and CMO at Harbour Biomed.
You may also be interested in...
2019 could be a monumental year for the South Korean pharma industry, as several new drug assets await the green light from the US FDA.
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll on the Korean firm and partner Evolus as they face a 10-year ban on imports of their product to the US.
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies, underscored by its early emergence from the global pandemic and focus on certain technologies, with Boehringer Ingelheim the latest to be attracted.